Chiasma, Inc. (CHMA): Product News News

CHMA – Has reached agreement with the FDA on the design of a new Phase 3 clinical trial for its octreotide capsules product candidate, Mycapssa, for the maintenance therapy of adult patients with acromegaly.


Key Facts Surrounding This News Item


  • CHMA had a POWR Rating of F (Strong Sell) coming into today.
  • CHMA was 2.47% above its 10-Day Moving Average coming into today.
  • CHMA was 1.58% above its 20-Day Moving Average coming into today.
  • CHMA was 1.38% above its 50-Day Moving Average coming into today.
  • CHMA was -3.88% below its 100-Day Moving Average coming into today.
  • CHMA was -16.07% below its 200-Day Moving Average coming into today.
  • CHMA had returned -25.64% year-to-date leading up to today’s news, versus a +11.63% return from the benchmark S&P 500 during the same period.

More Info About Chiasma, Inc. (CHMA)


Chiasma Inc. focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. The company was founded in 2001 and is based in Newton, Massachusetts. View our full CHMA ticker page with ratings, news, and more.

CHMA at a Glance

CHMA Current POWR Rating™
Overall POWR Rating™
CHMA Current Price $1.81 1.97%
More CHMA Ratings, Data, and News

CHMA Price Reaction

The day of this event (Aug. 10, 2017)
CHMA Closing Price$1.40 3.45%
CHMA Volume144,000
27.51% from avg
Leading up to this event
CHMA 1-mo return3.33%
After this event
CHMA 1-day return21.62%
CHMA 3-day return19.44%
CHMA 5-day return21.62%

CHMA Price Chart



More Chiasma, Inc. (CHMA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CHMA News
Page generated in 0.733 seconds.